Achillion Pharma Takeout Less Likely After Subpar Hep C Drug Results

Home › Achillion Pharma Takeout Less Likely After Subpar Hep C Drug Results

Tamp down your hopes and dreams if you were expecting Achillion to be the next hepatitis C buyout candidate. Achillion shares are up 18% to $16.84.

04.07	Atlantic Tropical Weather Outlook
04.07	Eastern North Pacific Tropical Weather Outlook
04.07	Hurricane Beryl Graphics
04.07	Hurricane Beryl Public Advisory Number 22A
04.07	Summary for Hurricane Beryl (AT2/AL022024)
04.07	Japan declares victory in 'war' on floppy disks
04.07	'Airport parking firms left us out of pocket'
04.07	Jeff Bezos to sell another $5bn of Amazon shares
More »

je.st